Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) Institutional Ownership
CUSIP: 61559X104
13F Institutional Holders and Ownership History from Q1 2022 to Q1 2026
Institutions Reporting
130
Shares (Excl. Options)
56,366,068
Price
$13.18
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Class A ordinary share, par value $0.0001 per share
- Symbol
- MLTX on Nasdaq
- Shares outstanding
- 71,754,637
- Price per share
- $18.64
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 56,366,068
- Total reported value
- $742,946,894
- % of total 13F portfolios
- 0%
- Share change
- +18,765,686
- Value change
- +$285,748,230
- Number of holders
- 130
- Price from insider filings
- $18.64
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- MLTX - MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share is tracked under CUSIP 61559X104.
- 130 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 130 to 3 between Q4 2025 and Q1 2026.
- Reported value moved from $742,946,894 to $3,382,631.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 130 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 61559X104?
CUSIP 61559X104 identifies MLTX - MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue With The Right Next Step
- Latest 13F filings - identify new institutional portfolio moves.
- Latest Schedule 13D/13G reports - cross-check beneficial ownership events.
- All institutional ownership pages - compare nearby CUSIPs and holder concentration.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 61559X104:
Significant Owners of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 22% | -19% | $283,062,714 | -$66,337,500 | 16,001,284 | -19% | BVF PARTNERS L P/IL | 31 Mar 2026 |
| Deep Track Capital, LP | 6.5% | $33,054,209 | 4,610,071 | Deep Track Capital, LP | 05 Nov 2025 | |||
| Cormorant Asset Management, LP | 6.1% | $74,477,904 | 4,355,433 | Cormorant Asset Management, LP | 31 Dec 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.7% | -12% | $117,334,991 | -$14,571,725 | 2,974,271 | -11% | T. Rowe Price Associates, Inc. | 31 Mar 2025 |
| Avoro Capital Advisors LLC | 3.2% | -48% | $14,340,000 | -$15,415,500 | 2,000,000 | -52% | Avoro Capital Advisors LLC | 30 Sep 2025 |
| Chen Bihua | 3.1% | $108,084,177 | 1,994,173 | Chen Bihua | 30 Sep 2025 | |||
| FMR LLC | 1.1% | -88% | $5,212,098 | -$35,678,759 | 726,931 | -87% | FMR LLC | 30 Sep 2025 |
As of 31 Dec 2025, 130 institutional investors reported holding 56,366,068 shares of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX). This represents 79% of the company’s total 71,754,637 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) together control 69% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BVF INC/IL | 28% | 19,751,284 | 0% | 8.8% | $260,321,923 |
| Deep Track Capital, LP | 6.4% | 4,610,071 | 1.4% | $60,760,736 | |
| Cormorant Asset Management, LP | 6.1% | 4,355,433 | +118% | 3.3% | $57,404,607 |
| D. E. Shaw & Co., Inc. | 3.5% | 2,480,767 | 0.02% | $32,696,509 | |
| JANUS HENDERSON GROUP PLC | 2.9% | 2,095,988 | +18783% | 0.01% | $27,656,562 |
| Logos Global Management LP | 2.4% | 1,750,000 | 1.5% | $23,065,000 | |
| JANE STREET GROUP, LLC | 2.3% | 1,682,148 | +7554% | 0.03% | $22,170,711 |
| Balyasny Asset Management L.P. | 2.2% | 1,571,071 | -7.5% | 0.04% | $20,706,716 |
| MORGAN STANLEY | 1.5% | 1,044,581 | +307% | 0% | $13,767,578 |
| Vivo Capital, LLC | 1.4% | 1,000,000 | 0.85% | $13,180,000 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.3% | 959,553 | +17% | 0% | $12,647,000 |
| JPMORGAN CHASE & CO | 1.2% | 837,739 | +381% | 0% | $11,041,400 |
| MILLENNIUM MANAGEMENT LLC | 1.1% | 802,722 | +800% | 0.01% | $10,579,876 |
| TWO SIGMA INVESTMENTS, LP | 1.1% | 784,811 | +73% | 0.02% | $10,343,809 |
| Point72 Asset Management, L.P. | 1.1% | 772,500 | +7783% | 0.02% | $10,181,550 |
| Nuveen, LLC | 0.89% | 637,434 | +0.27% | 0% | $8,401,380 |
| HRT FINANCIAL LP | 0.89% | 635,901 | +344% | 0.03% | $8,381,000 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.77% | 549,236 | +182% | 0.01% | $7,238,930 |
| Jefferies Financial Group Inc. | 0.7% | 500,000 | +1900% | 0.05% | $6,590,000 |
| Voleon Capital Management LP | 0.7% | 499,099 | +1139% | 0.14% | $6,578,125 |
| Jump Financial, LLC | 0.59% | 425,559 | 0.07% | $5,608,868 | |
| Soleus Capital Management, L.P. | 0.56% | 400,000 | 0.22% | $5,272,000 | |
| CITADEL ADVISORS LLC | 0.53% | 380,890 | +672% | 0% | $5,020,130 |
| Rhenman & Partners Asset Management AB | 0.51% | 364,000 | +76% | 0.45% | $4,797,520 |
| STEMPOINT CAPITAL LP | 0.49% | 348,401 | 0.79% | $4,591,925 |
Institutional Holders of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 181,555 | $3,382,631 | +$2,018,295 | $18.64 | 3 |
| 2025 Q4 | 56,366,068 | $742,946,894 | +$285,748,230 | $13.18 | 130 |
| 2025 Q3 | 37,454,837 | $268,355,896 | -$543,765,841 | $7.17 | 132 |
| 2025 Q2 | 58,588,386 | $2,765,378,029 | -$36,637,296 | $47.20 | 129 |
| 2025 Q1 | 59,723,013 | $2,333,397,891 | -$153,122,113 | $39.07 | 134 |
| 2024 Q4 | 63,244,825 | $3,424,722,298 | +$68,390,992 | $54.15 | 114 |
| 2024 Q3 | 62,105,859 | $3,131,140,770 | +$81,133,174 | $50.42 | 108 |
| 2024 Q2 | 60,656,094 | $2,667,012,692 | +$45,095,266 | $43.97 | 109 |
| 2024 Q1 | 59,346,206 | $2,980,958,004 | +$1,466,170 | $50.23 | 112 |
| 2023 Q4 | 58,433,271 | $3,528,831,635 | +$147,969,282 | $60.39 | 124 |
| 2023 Q3 | 56,323,727 | $3,210,450,399 | +$46,563,145 | $57.00 | 118 |
| 2023 Q2 | 56,057,516 | $2,858,934,462 | +$861,230,424 | $51.00 | 82 |
| 2023 Q1 | 39,419,149 | $843,176,754 | +$59,244,738 | $21.39 | 43 |
| 2022 Q4 | 37,748,780 | $396,358,589 | +$8,234,061 | $10.50 | 32 |
| 2022 Q3 | 36,855,847 | $291,356,995 | +$3,123,162 | $7.76 | 24 |
| 2022 Q2 | 36,470,008 | $190,106,000 | +$182,848,000 | $5.25 | 22 |
| 2022 Q1 | 653,872 | $7,258,000 | +$7,258,000 | $11.10 | 1 |